Research progress of copper transporter 1 in platinum-based chemotherapy.
10.11817/j.issn.1672-7347.2018.12.015
- Author:
Qianying OUYANG
1
,
2
,
3
;
Yujie LIU
1
,
2
,
3
;
Yingzi LIU
1
,
2
,
3
Author Information
1. Department of Clinical Pharmacology, Xiangya Hospital, Central South University, Changsha 410008
2. Institute of Clinical Pharmacology, Central South University
3. Hunan Key Laboratory of Pharmacogenetics, Changsha 410078, China.
- Publication Type:Journal Article
- MeSH:
Antineoplastic Agents;
therapeutic use;
Cation Transport Proteins;
genetics;
metabolism;
Cisplatin;
therapeutic use;
Copper;
Copper Transporter 1;
Drug Resistance, Neoplasm;
genetics;
Platinum;
therapeutic use;
Research;
trends
- From:
Journal of Central South University(Medical Sciences)
2018;43(12):1376-1379
- CountryChina
- Language:Chinese
-
Abstract:
Platinum drugs are widely used in the treatment of various solid tumors, but their resistance to platinum is the most significant obstacle to successful treatment. Copper transporter 1 (CTR1) is the specific transporter for copper, and it mainly locates at the plasma membrane and plays a role in pumping copper into the cell. CTR1 is also the major platinum influx transporter and plays a key role in platinum resistance. The expression, polymorphism, and degradation of CTR1 affect platinum resistance in tumors. Therefore, CTR1 may be a potential predictive biomarker of platinum resistance and a therapeutic target for overcoming platinum resistance.
